Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Endocrine therapy

References

1 National Breast Cancer Centre. Clinical practice guidelines for the management of advanced breast cancer. Canberra: Commonwealth of Australia 2001.

2 Klijn JGM, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LH-RH) agonist versus LH-RH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001;19(2):343–353.

3 National Breast and Ovarian Cancer Centre. Evidence of the use of endocrine therapy for post-menopausal women with metastatic breast cancer. National Breast and Ovarian Cancer Centre, Surry Hills, NSW, 2008.

4 Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD002747. DOI: 10.1002/14651858.CD002747.

5 Klijn JGM, Beex VAM, Mauriac L, et al. Combined Treatment With Buserelin and Tamoxifen in Premenopasual Metastatic Breast Cancer: A Randomised Study. J Nat Cancer Inst 2000; 92 (11): 903–911.

6 Bonneterre J, Buzdar A, NabholtzJA, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92(9):2247–58.

7 Milla-Santos A, Milla L, Portella J, et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer. A J Clin Oncol 2003; 26(3):317–22.

8 Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391–8.

9 Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 2001;19(10):2596–606.

10 Batra U, Jacob LA, Saini KS, Dadhich HK. To analyze the efficacy, tolerability and pharmaco economics of letrozole vs. tamoxifen as first-line therapy in post menopausal, hormone positive females with metastatic or recurrent breast cancer. Ann Oncol 2006;17(Suppl 9): ix77.

11 Budzar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analsyis of two phase III trials. J Clin Oncol 1996;14(2000–11).

12 Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane improves survival compared with megestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: results of a double-blind randomised phase III trial. Euro Cancer 2000;36(Suppl):81–91.

13 Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19(14):3357–66.

14 Schmid P, Wischnewsky MB, Possinger K. Self organizing maps and prognosis of advanced breast cancer patients with bone metastases receiving letrozole or MA. Breast Cancer Res and Treat 2001;64:77.

15 Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16(2):453–61.

16 Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ, Osborne CK. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Euro J Cancer 2003;39(9):1228–33.

17 Gradishar W, Chia S, Piccart M, on behalf of the EFECT writing committee. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. 29th Annual San Antonio Breast Cancer Symposium, December 2006, Abstract 12.

18 Mayordomo J, Llombart A, Martin M, et al. Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study. ASCO Annual Meeting 2006, abstract no. 638.

19 Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. Euro J Cancer 2003;39(16):2318–27.

20 National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. Canberra, Commonwealth of Australia, 2000.

21 National Breast Cancer Centre. Recommendations for use of Trastuzumab (Herceptin®) for treatment of HER2-positive breast cancer. NBCC, Camperdown, NSW, 2007.

22 National Breast Cancer Centre and National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. NBCC, Camperdown, NSW, 2003.

23 Therapeutic Good Administration http:/www.tga.gov.au/ Accessed October 10, 2007.

24 National Cancer Institute Clinical Trials (PDQ®) D8664C00008, Zoladex ABC Studyhttp://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=484695&version=patient&protocolsearchpr=3592790 Accessed August 31, 2007.

25 National Cancer Institute Clinical Trials (PDQ®) UWCC-UW 6412http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=553612&version=patient&protocolsearchid=3592790 Accessed August 31, 2007.

26 National Cancer Institute Clinical Trials (PDQ®) SWOG-8692 http://www.nci.nih.gov/clinicaltrials/view_clinicaltrials.aspx?version=healthprofessional&cdrid=74317&protocolsearchid=842037 Accessed August 31, 2007.

27 National Cancer Institute Clinical Trials (PDQ®) FIRST http://clinicaltrials.gov/ct/show/NCT00274469?order=1 Accessed August 31, 2007.

28 National Cancer Institute Clinical Trials (PDQ®) SWOG-S0226 http://www.cancer.gov/clinicaltrials/SWOG-S0226 Accessed August 31, 2007.

29 National Cancer Institute Clinical Trials (PDQ®) EORTC-10951 http://www.cancer.gov/clinicaltrials/EORTC-10951 Accessed August 31, 2007.

30 National Cancer Institute Clinical Trials (PDQ®) ICR-CTSU Sofea http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=448616&version=patient&protocolsearchid=3592790 Accessed August 31, 2007.

31 National Cancer Institute Clinical Trials (PDQ®) D6997L00004http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=487687&version=HealthProfessional&protocolsearchid=3594517 Accessed August 31, 2007.

32 Clinical Trials EFECT http://clinicaltrials.gov/ct/show/NCT00065325?order=1 Accessed August 31, 2007.

33 National Cancer Institute Clinical Trials (PDQ®) A5991048http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=447079&version=patient&protocolsearchid=3592790 Accessed August 31, 2007.

34 GEICAM 2001-03 http://www.geicam.org/ingles/protocolgeicam2001-03.htm Accessed August 31, 2007.

Published using CeCC Docbook Manager